Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 46 of 363 for:    transthyretin

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02510261
Recruitment Status : Active, not recruiting
First Posted : July 29, 2015
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2022